The new "Regulation for Medical Device Administration and Supervision", Order 739 was released on Mar 18, 2021. The effective date is June 1, 2021. It will replace Order 680. Order 739 is a long-awaited overarching policy regulating NMPA medical device and IVD, covering 8 chapters and 107 articles for the complete product life cycle. Article 53 allows the development of laboratory developed test (LDT) in China.
Article 53 states that "If there is no product of the same type that has China market approval, the eligible medical institutions can develop their own in vitro diagnostic reagents (IVD) based on the clinical needs of the institutions. Such in-house developed IVD reagents can be used in the institutions under the guidance of a licensed physician." This new regulation relaxes the restrictions on LDTs in China-allowing China medical institutions to develop their own IVD reagents under certain conditions:
Although at this stage, both the development and usage are restricted within the eligible medical institutions, the Independent Clinical Laboratories (ICL) and molecular diagnostic companies can benefit from this new regulation through collaboration with medical institutions in China. The eased restriction will certainly help to accelerate the development in new IVD products.
I would love to hear your feedback on overseas companies can benefit from this. If you need the complete English version of "Regulation for Medical Device Administration and Supervision", Order 739, please email me at gpalma@ChinaMedDevice.com
Regulatory Affairs Professionals Society (RAPS)5635 Fishers Lane, Suite 400Rockville, Maryland 20852
email@example.com+1 301 770 2920
JoinMy RAPS DashboardLearn More